vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and Grace Therapeutics, Inc. (GRCE). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Delix Therapeutics is an American biotech company based in Boston, Massachusetts. The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD). It was co-founded in 2019 by David E. Olson and Nick Haft.
ASBP vs GRCE — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2022
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | $-3.8M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | -17.3% |
| EPS (diluted) | $-0.04 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $46.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $111.1M |
| Total Assets | $2.4M | $114.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q4 21 | — | $46.3M |
| Q3 25 | $-11.5M | — | ||
| Q4 21 | — | $111.1M |
| Q3 25 | $2.4M | — | ||
| Q4 21 | — | $114.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-4.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-1.1M | — | ||
| Q4 21 | — | $-4.6M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
